These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25170252)

  • 1. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.
    Devarakonda K; Morton T; Margulis R; Giuliani M; Barrett T
    Drug Des Devel Ther; 2014; 8():1125-34. PubMed ID: 25170252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets.
    Morton T; Franke R; Devarakonda K
    Pain Pract; 2016 Jul; 16(6):730-6. PubMed ID: 26218586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials.
    Barrett T; Kostenbader K; Nalamachu S; Giuliani M; Young JL
    Pain Pract; 2016 Sep; 16(7):856-68. PubMed ID: 26296448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.
    Morton T; Kostenbader K; Montgomery J; Devarakonda K; Barrett T; Webster L
    Postgrad Med; 2014 Jul; 126(4):20-32. PubMed ID: 25141240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Eisenhauer TD; Matchett M; Heasley R; Morton T; Devarakonda K; Giuliani M; Young JL; Barrett T
    Drug Dev Ind Pharm; 2016 Jan; 42(1):157-165. PubMed ID: 26146769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, immediate-release and extended-release combination analgesic for acute pain.
    Singla N; Barrett T; Sisk L; Kostenbader K; Young J; Giuliani M
    Curr Med Res Opin; 2014 Mar; 30(3):349-59. PubMed ID: 24351079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the safety and efficacy of extended-release oxycodone/acetaminophen, for 14 days postsurgery.
    Singla N; Barrett T; Sisk L; Kostenbader K; Young J
    Curr Med Res Opin; 2014 Dec; 30(12):2571-8. PubMed ID: 25157951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
    Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
    Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
    Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
    Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
    Perrino PJ; Colucci SV; Apseloff G; Harris SC
    Clin Drug Investig; 2013 Jun; 33(6):441-9. PubMed ID: 23677743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
    Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.